<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878511</url>
  </required_header>
  <id_info>
    <org_study_id>2019_Lactose_microbiota</org_study_id>
    <nct_id>NCT03878511</nct_id>
  </id_info>
  <brief_title>Therapeutic Lactose to Support Vaginal Microbiota</brief_title>
  <official_title>Effect of Vaginal Lactose on the Vaginal Microbiota in Women With Bacterial Vaginosis: Double-blind, Placebo-controlled Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Humaidan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regionshospitalet Viborg, Skive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to investigate whether the administration of a vaginal tablet
      containing lactose can modulate the bacterial flora of women with bacterial vaginosis (BV).

      Design: Double-blind, placebo-controlled randomised trial.

      Setting: Women with BV who responded to advertisements in local newspapers and on posters at
      the Institutions for Education in Health Science in Eastern Jutland, Denmark. These
      individuals were supplemented with patients enrolled at a gynaecological clinic.

      Participants: Forty women with BV diagnosed through the Amsel test. By randomisation, 20 were
      assigned to receive lactose tablets, and 20 were assigned to receive placebo tablets.

      Interventions: Twice daily application of one lactose tablet or placebo tablet for 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2012</start_date>
  <completion_date type="Actual">March 1, 2013</completion_date>
  <primary_completion_date type="Actual">March 1, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Active and inactive tablets were identical. The tablets were packed and labelled by the manufacturer. The key to identity was retained and was disclosed after recruiting all patients. After informed consent, eligible patients drew a closed opaque envelope from a set of envelopes numbered 1-40 and placed in random order. The envelope contained both number labels for medical data-related documents and sample vials and a closed opaque container holding tablets labelled with the sample number.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial load after intervention</measure>
    <time_frame>7 days</time_frame>
    <description>quantitative measurements with qPCR for G. vaginalis, Prevotella spp., A. vaginae, Megasphaera type 1, L. gasseri, L. crispatus, L. jensenii and L. iners after intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bacterial Vaginoses</condition>
  <arm_group>
    <arm_group_label>Lactose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactose</intervention_name>
    <description>Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg</description>
    <arm_group_label>Lactose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Amsel criteria positive defined as 3/4 of the following: Vaginal discharge, Fishy
             odor, pH&gt;4.5 and Clue cells in a wet smear.

        Exclusion Criteria:

          -  Not able to provide written informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regionshospitalet Viborg, Skive</investigator_affiliation>
    <investigator_full_name>Peter Humaidan</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

